Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Immunocore Holdings PLC - ADR before investing.

In this article, we go over a few key elements for understanding Immunocore Holdings PLC - ADR’s stock price such as:

• Immunocore Holdings PLC - ADR’s current stock price and volume
• Why Immunocore Holdings PLC - ADR’s stock price changed recently
• Upgrades and downgrades for IMCR from analysts
• IMCR’s stock price momentum as measured by its relative strength

About Immunocore Holdings PLC - ADR (IMCR)

Before we jump into Immunocore Holdings PLC - ADR’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.

Want to learn more about Immunocore Holdings PLC - ADR’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Immunocore Holdings PLC - ADR.

Immunocore Holdings PLC - ADR’s Stock Price as of Market Close

As of May 31, 2024, 4:00 PM, CST, Immunocore Holdings PLC - ADR’s stock price was $48.98.

Immunocore Holdings PLC - ADR is up 4.86% from its previous closing price of $46.71.

During the last market session, Immunocore Holdings PLC - ADR’s stock traded between $46.06 and $47.37. Currently, there are 49.88 million shares of Immunocore Holdings PLC - ADR stock available for purchase.

Unfortunately, Immunocore Holdings PLC - ADR’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Immunocore Holdings PLC - ADR Stock Price History

Immunocore Holdings PLC - ADR’s (IMCR) price is currently down 17.1% so far this month.

During the month of May, Immunocore Holdings PLC - ADR’s stock price has reached a high of $62.74 and a low of $41.01.

Over the last year, Immunocore Holdings PLC - ADR has hit prices as high as $76.98 and as low as $41.01. Year to date, Immunocore Holdings PLC - ADR’s stock is down 14.18%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Immunocore Holdings PLC - ADR Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 30, 2024, there were 13 analysts who downgraded Immunocore Holdings PLC - ADR’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Immunocore Holdings PLC - ADR’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Immunocore Holdings PLC - ADR’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Immunocore Holdings PLC - ADR’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Immunocore Holdings PLC - ADR (IMCR) by visiting AAII Stock Evaluator.

Relative Price Strength of Immunocore Holdings PLC - ADR

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 30, 2024, Immunocore Holdings PLC - ADR has a weighted four-quarter relative price strength of -12.33%, which translates to a Momentum Score of 26 and is considered to be Weak.

Want to learn more about how Immunocore Holdings PLC - ADR is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Immunocore Holdings PLC - ADR Stock Price: Bottom Line

As of May 31, 2024, Immunocore Holdings PLC - ADR’s stock price is $48.98, which is up 4.86% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Immunocore Holdings PLC - ADR stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.